VTN and Alzheimer disease: Complement proteins (C1q, C3b, and C3d) and complement regulatory proteins (CD59, CD46, decay‐accelerating factor, and complement receptor type 1) in astrocyte‐derived exosomes (ADEs) can be further elevated or decreased as the disease progresses, and therefore, measurement of the levels of complement proteins in the exosomes can predict AD progression.210